-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Medical Network News on August 25 A few days ago, Sichuan Kelun Pharmaceutical Co.
, Ltd.
entered the administrative examination and approval stage with the imitation of 4 types of canagliflozin tablets for production
.
According to data from Mi Nei.
com, the terminal sales growth rate of this product in China's public medical institutions will exceed 1000% in 2020
.
At present, 4 SGLT-2 inhibitors have been approved in China, with a total sales scale of more than 1 billion yuan
.
, Ltd.
entered the administrative examination and approval stage with the imitation of 4 types of canagliflozin tablets for production
.
According to data from Mi Nei.
com, the terminal sales growth rate of this product in China's public medical institutions will exceed 1000% in 2020
.
At present, 4 SGLT-2 inhibitors have been approved in China, with a total sales scale of more than 1 billion yuan
.
Source: official website of the State Drug Administration
Canagliflozin (also known as canagliflozin) is an oral hypoglycemic drug developed by Johnson & Johnson.
It was approved for marketing in the United States in March 2013.
It is the first sodium-glucose cotransporter-2 (SGLT) approved by the FDA.
-2) Inhibitors, reaching a global sales peak of 1.
4 billion U.
S.
dollars in 2016
.
It was approved for marketing in the United States in March 2013.
It is the first sodium-glucose cotransporter-2 (SGLT) approved by the FDA.
-2) Inhibitors, reaching a global sales peak of 1.
4 billion U.
S.
dollars in 2016
.
The original research product was approved for import in October 2017, and was included in the National Medical Insurance Category B catalog through negotiations in 2019.
In 2020, it will be used in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (referred to as Chinese public medical institutions).
Sales exceeded 60 million yuan, a year-on-year increase of 1174.
56%
.
In 2020, it will be used in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (referred to as Chinese public medical institutions).
Sales exceeded 60 million yuan, a year-on-year increase of 1174.
56%
.
At present, 8 domestic companies have submitted applications for the listing of canagliflozin with imitations of Category 4.
The products of Hausen and Chia Tai Tianqing have been successfully approved and deemed to have been reviewed, and they have won the bid in the fourth batch of centralized procurement
.
Kelun Pharmaceutical's products have recently entered the administrative examination and approval stage, sprinting into the third domestic market
.
The products of Hausen and Chia Tai Tianqing have been successfully approved and deemed to have been reviewed, and they have won the bid in the fourth batch of centralized procurement
.
Kelun Pharmaceutical's products have recently entered the administrative examination and approval stage, sprinting into the third domestic market
.
As a rising star in the oral hypoglycemic drug market, the market size of SGLT-2 inhibitors has expanded rapidly after the launch
.
According to data from the global drug research and development database of Meinenet, there are currently 8 SGLT-2 inhibitors (excluding the compound, the same below) are on the market worldwide, namely dapagliflozin, repaggliflozin, enpagliflozin, and canagliflozin.
, Togligliflozin, iggliflozin, ruggliflozin and aeggliflozin
.
.
According to data from the global drug research and development database of Meinenet, there are currently 8 SGLT-2 inhibitors (excluding the compound, the same below) are on the market worldwide, namely dapagliflozin, repaggliflozin, enpagliflozin, and canagliflozin.
, Togligliflozin, iggliflozin, ruggliflozin and aeggliflozin
.
Among them, Johnson & Johnson’s canagliflozin (October 2017), AstraZeneca’s dapagliflozin (March 2017), Boehringer Ingelheim/Lilly’s Enpagliflozin (September 2017), Merck & Co.
/Pfizer's Ieggliflozin (August 2020) 4 SGLT-2 inhibitors have been approved for import, and the first 3 models have been negotiated and included in the National Medical Insurance Category B list in 2019
.
/Pfizer's Ieggliflozin (August 2020) 4 SGLT-2 inhibitors have been approved for import, and the first 3 models have been negotiated and included in the National Medical Insurance Category B list in 2019
.
According to data from Mi Nei.
com, the market size of SGLT-2 inhibitors in China's public medical institutions and Chinese urban physical pharmacies will exceed 1 billion yuan in 2020 , a year-on-year increase of 232.
6%
.
com, the market size of SGLT-2 inhibitors in China's public medical institutions and Chinese urban physical pharmacies will exceed 1 billion yuan in 2020 , a year-on-year increase of 232.
6%
.
Sales of terminal SGLT-2 inhibitors in physical pharmacies in cities in China (unit: ten thousand yuan)
Source: Mi Nei.
com, China's urban physical pharmacy terminal competition pattern
com, China's urban physical pharmacy terminal competition pattern
In the initial launch of several SGLT-2 inhibitors, the terminal sales of physical pharmacies in Chinese cities were higher than those of public medical institutions in China.
With the increase in medical insurance, the growth rate of several products in physical pharmacies in Chinese cities slowed down, but the overall market Still showing an upward trend
.
With the increase in medical insurance, the growth rate of several products in physical pharmacies in Chinese cities slowed down, but the overall market Still showing an upward trend
.
Source: Mi Nei.
com database, official website of the State Drug Administration, etc.
com database, official website of the State Drug Administration, etc.
Note: China's urban entity pharmacy terminal competition pattern database is an enlarged version of the urban entity pharmacy database that covers 293 prefectures and cities across the country (excluding county and rural entity pharmacies), and continuously monitors all categories
.
The above sales are calculated based on the average retail price of the product at the terminal
.
Statistics are as of August 24, if there are any omissions, please correct me!
.
The above sales are calculated based on the average retail price of the product at the terminal
.
Statistics are as of August 24, if there are any omissions, please correct me!
Medical Network News on August 25 A few days ago, Sichuan Kelun Pharmaceutical Co.
, Ltd.
entered the administrative examination and approval stage with the imitation of 4 types of canagliflozin tablets for production
.
According to data from Mi Nei.
com, the terminal sales growth rate of this product in China's public medical institutions will exceed 1000% in 2020
.
At present, 4 SGLT-2 inhibitors have been approved in China, with a total sales scale of more than 1 billion yuan
.
, Ltd.
entered the administrative examination and approval stage with the imitation of 4 types of canagliflozin tablets for production
.
According to data from Mi Nei.
com, the terminal sales growth rate of this product in China's public medical institutions will exceed 1000% in 2020
.
At present, 4 SGLT-2 inhibitors have been approved in China, with a total sales scale of more than 1 billion yuan
.
Source: official website of the State Drug Administration
Canagliflozin (also known as canagliflozin) is an oral hypoglycemic drug developed by Johnson & Johnson.
It was approved for marketing in the United States in March 2013.
It is the first sodium-glucose cotransporter-2 (SGLT) approved by the FDA.
-2) Inhibitors, reaching a global sales peak of 1.
4 billion U.
S.
dollars in 2016
.
It was approved for marketing in the United States in March 2013.
It is the first sodium-glucose cotransporter-2 (SGLT) approved by the FDA.
-2) Inhibitors, reaching a global sales peak of 1.
4 billion U.
S.
dollars in 2016
.
The original research product was approved for import in October 2017, and was included in the National Medical Insurance Category B catalog through negotiations in 2019.
In 2020, it will be used in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (referred to as Chinese public medical institutions).
Sales exceeded 60 million yuan, a year-on-year increase of 1174.
56%
.
In 2020, it will be used in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (referred to as Chinese public medical institutions).
Sales exceeded 60 million yuan, a year-on-year increase of 1174.
56%
.
At present, 8 domestic companies have submitted applications for the listing of canagliflozin with imitations of Category 4.
The products of Hausen and Chia Tai Tianqing have been successfully approved and deemed to have been reviewed, and they have won the bid in the fourth batch of centralized procurement
.
Kelun Pharmaceutical's products have recently entered the administrative examination and approval stage, sprinting into the third domestic market
.
The products of Hausen and Chia Tai Tianqing have been successfully approved and deemed to have been reviewed, and they have won the bid in the fourth batch of centralized procurement
.
Kelun Pharmaceutical's products have recently entered the administrative examination and approval stage, sprinting into the third domestic market
.
As a rising star in the oral hypoglycemic drug market, the market size of SGLT-2 inhibitors has expanded rapidly after the launch
.
According to data from the global drug research and development database of Meinenet, there are currently 8 SGLT-2 inhibitors (excluding the compound, the same below) are on the market worldwide, namely dapagliflozin, repaggliflozin, enpagliflozin, and canagliflozin.
, Togligliflozin, iggliflozin, ruggliflozin and aeggliflozin
.
.
According to data from the global drug research and development database of Meinenet, there are currently 8 SGLT-2 inhibitors (excluding the compound, the same below) are on the market worldwide, namely dapagliflozin, repaggliflozin, enpagliflozin, and canagliflozin.
, Togligliflozin, iggliflozin, ruggliflozin and aeggliflozin
.
Among them, Johnson & Johnson’s canagliflozin (October 2017), AstraZeneca’s dapagliflozin (March 2017), Boehringer Ingelheim/Lilly’s Enpagliflozin (September 2017), Merck & Co.
/Pfizer's Ieggliflozin (August 2020) 4 SGLT-2 inhibitors have been approved for import, and the first 3 models have been negotiated and included in the National Medical Insurance Category B list in 2019
.
/Pfizer's Ieggliflozin (August 2020) 4 SGLT-2 inhibitors have been approved for import, and the first 3 models have been negotiated and included in the National Medical Insurance Category B list in 2019
.
According to data from Mi Nei.
com, the market size of SGLT-2 inhibitors in China's public medical institutions and Chinese urban physical pharmacies will exceed 1 billion yuan in 2020 , a year-on-year increase of 232.
6%
.
com, the market size of SGLT-2 inhibitors in China's public medical institutions and Chinese urban physical pharmacies will exceed 1 billion yuan in 2020 , a year-on-year increase of 232.
6%
.
Sales of terminal SGLT-2 inhibitors in physical pharmacies in cities in China (unit: ten thousand yuan)
Source: Mi Nei.
com, China's urban physical pharmacy terminal competition pattern
com, China's urban physical pharmacy terminal competition pattern
In the initial launch of several SGLT-2 inhibitors, the terminal sales of physical pharmacies in Chinese cities were higher than those of public medical institutions in China.
With the increase in medical insurance, the growth rate of several products in physical pharmacies in Chinese cities slowed down, but the overall market Still showing an upward trend
.
With the increase in medical insurance, the growth rate of several products in physical pharmacies in Chinese cities slowed down, but the overall market Still showing an upward trend
.
Source: Mi Nei.
com database, official website of the State Drug Administration, etc.
com database, official website of the State Drug Administration, etc.
Note: China's urban entity pharmacy terminal competition pattern database is an enlarged version of the urban entity pharmacy database that covers 293 prefectures and cities across the country (excluding county and rural entity pharmacies), and continuously monitors all categories
.
The above sales are calculated based on the average retail price of the product at the terminal
.
Statistics are as of August 24, if there are any omissions, please correct me!
.
The above sales are calculated based on the average retail price of the product at the terminal
.
Statistics are as of August 24, if there are any omissions, please correct me!
Medical Network News on August 25 A few days ago, Sichuan Kelun Pharmaceutical Co.
, Ltd.
entered the administrative examination and approval stage with the imitation of 4 types of canagliflozin tablets for production
.
According to data from Mi Nei.
com, the terminal sales growth rate of this product in China's public medical institutions will exceed 1000% in 2020
.
At present, 4 SGLT-2 inhibitors have been approved in China, with a total sales scale of more than 1 billion yuan
.
, Ltd.
entered the administrative examination and approval stage with the imitation of 4 types of canagliflozin tablets for production
.
According to data from Mi Nei.
com, the terminal sales growth rate of this product in China's public medical institutions will exceed 1000% in 2020
.
At present, 4 SGLT-2 inhibitors have been approved in China, with a total sales scale of more than 1 billion yuan
.
Source: official website of the State Drug Administration
Canagliflozin (also known as canagliflozin) is an oral hypoglycemic drug developed by Johnson & Johnson.
It was approved for marketing in the United States in March 2013.
It is the first sodium-glucose cotransporter-2 (SGLT) approved by the FDA.
-2) Inhibitors, reaching a global sales peak of 1.
4 billion U.
S.
dollars in 2016
.
It was approved for marketing in the United States in March 2013.
It is the first sodium-glucose cotransporter-2 (SGLT) approved by the FDA.
-2) Inhibitors, reaching a global sales peak of 1.
4 billion U.
S.
dollars in 2016
.
The original research product was approved for import in October 2017, and was included in the National Medical Insurance Category B catalog through negotiations in 2019.
In 2020, it will be used in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (referred to as Chinese public medical institutions).
Sales exceeded 60 million yuan, a year-on-year increase of 1174.
56%
.
Hospital hospital hospitalIn 2020, it will be used in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (referred to as Chinese public medical institutions).
Sales exceeded 60 million yuan, a year-on-year increase of 1174.
56%
.
At present, 8 domestic companies have submitted applications for the listing of canagliflozin with imitations of Category 4.
The products of Hausen and Chia Tai Tianqing have been successfully approved and deemed to have been reviewed, and they have won the bid in the fourth batch of centralized procurement
.
Kelun Pharmaceutical's products have recently entered the administrative examination and approval stage, sprinting into the third domestic market
.
Enterprise business enterpriseThe products of Hausen and Chia Tai Tianqing have been successfully approved and deemed to have been reviewed, and they have won the bid in the fourth batch of centralized procurement
.
Kelun Pharmaceutical's products have recently entered the administrative examination and approval stage, sprinting into the third domestic market
.
As a rising star in the oral hypoglycemic drug market, the market size of SGLT-2 inhibitors has expanded rapidly after the launch
.
According to data from the global drug research and development database of Meinenet, there are currently 8 SGLT-2 inhibitors (excluding the compound, the same below) are on the market worldwide, namely dapagliflozin, repaggliflozin, enpagliflozin, and canagliflozin.
, Togligliflozin, iggliflozin, ruggliflozin and aeggliflozin
.
.
According to data from the global drug research and development database of Meinenet, there are currently 8 SGLT-2 inhibitors (excluding the compound, the same below) are on the market worldwide, namely dapagliflozin, repaggliflozin, enpagliflozin, and canagliflozin.
, Togligliflozin, iggliflozin, ruggliflozin and aeggliflozin
.
Among them, Johnson & Johnson’s canagliflozin (October 2017), AstraZeneca’s dapagliflozin (March 2017), Boehringer Ingelheim/Lilly’s Enpagliflozin (September 2017), Merck & Co.
/Pfizer's Ieggliflozin (August 2020) 4 SGLT-2 inhibitors have been approved for import, and the first 3 models have been negotiated and included in the National Medical Insurance Category B list in 2019
.
/Pfizer's Ieggliflozin (August 2020) 4 SGLT-2 inhibitors have been approved for import, and the first 3 models have been negotiated and included in the National Medical Insurance Category B list in 2019
.
According to data from Mi Nei.
com, the market size of SGLT-2 inhibitors in China's public medical institutions and Chinese urban physical pharmacies will exceed 1 billion yuan in 2020 , a year-on-year increase of 232.
6%
.
Pharmacy pharmacy pharmacycom, the market size of SGLT-2 inhibitors in China's public medical institutions and Chinese urban physical pharmacies will exceed 1 billion yuan in 2020 , a year-on-year increase of 232.
6%
.
Sales of terminal SGLT-2 inhibitors in physical pharmacies in cities in China (unit: ten thousand yuan)
Source: Mi Nei.
com, China's urban physical pharmacy terminal competition pattern
com, China's urban physical pharmacy terminal competition pattern
In the initial launch of several SGLT-2 inhibitors, the terminal sales of physical pharmacies in Chinese cities were higher than those of public medical institutions in China.
With the increase in medical insurance, the growth rate of several products in physical pharmacies in Chinese cities slowed down, but the overall market Still showing an upward trend
.
With the increase in medical insurance, the growth rate of several products in physical pharmacies in Chinese cities slowed down, but the overall market Still showing an upward trend
.
Source: Mi Nei.
com database, official website of the State Drug Administration, etc.
com database, official website of the State Drug Administration, etc.
Note: China's urban entity pharmacy terminal competition pattern database is an enlarged version of the urban entity pharmacy database that covers 293 prefectures and cities across the country (excluding county and rural entity pharmacies), and continuously monitors all categories
.
The above sales are calculated based on the average retail price of the product at the terminal
.
Statistics are as of August 24, if there are any omissions, please correct me!
.
The above sales are calculated based on the average retail price of the product at the terminal
.
Statistics are as of August 24, if there are any omissions, please correct me!
